High Point Advisor Group LLC Halozyme Therapeutics, Inc. Transaction History
High Point Advisor Group LLC
- $1.7 Billion
- Q1 2025
A detailed history of High Point Advisor Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, High Point Advisor Group LLC holds 5,023 shares of HALO stock, worth $267,776. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,023
Previous 5,982
16.03%
Holding current value
$267,776
Previous $285,000
12.28%
% of portfolio
0.02%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$939 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$684 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$323 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$208 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$196 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.43B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...